CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi therapeutics, today announced that new clinical data from a Phase 1 study of DCR-MYC in patients with solid tumors, multiple myeloma, or lymphoma will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29-June 2, 2015 in Chicago. DCR-MYC is an investigational Dicer substrate short interfering RNA (DsiRNA) therapeutic targeting the MYC oncogene and the first MYC-targeting short interfering RNA (siRNA) to enter clinical trials. DCR-MYC is currently in two Phase 1 trials in patients with multiple tumor types.
Help employers find you! Check out all the jobs and post your resume.
